A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling
- Author
- JULKA, P. K1 ; CHACKO, R. T2 ; DHINDSA, N5 ; MILLER, I. D6 ; MA, D7 ; LIN, B7 ; AWASTHY, B8 ; PEROUOU, C. M4 ; NAG, S3 ; PARSHAD, R1 ; NAIR, A2 ; OH, D. S4 ; HU, Z4 ; KOPPIKER, C. B3 ; NAIR, S2 ; DAWAR, R1
[1] Department of Radiotherapy and Oncology, AIIMS, New Delhi 110029, India
[2] Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu 632004, India
[3] Department of Medical Oncology, HCJMRI, Pune, Maharashtra 411001, India
[4] Departments of Genetics and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
[5] Eli Lilly and Company (India) Pvt. Ltd, Gurgaon, Haryana 122001, India
[6] Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
[7] Eli Lilly and Company, Indianapolis, IN 46285, United States
[8] Health Care Global Enterprises, Curie Centre of Oncology, St John's Hospital Campus, Koramangala, Bangalore 560034, India - Source
British journal of cancer. 2008, Vol 98, Num 8, pp 1327-1335, 9 p ; ref : 1 p.1/4
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- breast cancer chemotherapy gemcitabine gene expression microarrays neoadjuvant therapy
- Keyword (fr)
- Anticancéreux Cancer du sein Cancérologie Chimiothérapie Cisplatine Doxorubicine Essai clinique phase II Expression génique Facteur prédictif Gemcitabine Homme Séquentiel Traitement néoadjuvant Agent alkylant Anthracyclines Antimétabolite Cancer DNA topoisomerase (ATP-hydrolysing) Dérivé de la pyrimidine Enzyme Fluor Composé organique Inhibiteur de la topoisomérase II Inhibiteur enzyme Isomerases Pathologie de la glande mammaire Pathologie du sein Platine II Complexe Pyrimidine nucléoside Traitement Tumeur maligne
- Keyword (en)
- Antineoplastic agent Breast cancer Cancerology Chemotherapy Cisplatin Doxorubicin Phase II trial Gene expression Predictive factor Gemcitabine Human Sequential Neoadjuvant treatment Alkylating agent Anthracyclins Antimetabolic Cancer DNA topoisomerase (ATP-hydrolysing) Pyrimidine derivatives Enzyme Fluorine Organic compounds Topoisomerase II inhibitor Enzyme inhibitor Isomerases Mammary gland diseases Breast disease Platinum II Complexes Pyrimidine nucleoside Treatment Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pecho Cancerología Quimioterapia Cisplatino Doxorubicina Ensayo clínico fase II Expresión genética Factor predictivo Gemcitabina Hombre Secuencial Neocoadyuvante tratamiento Agente alquilante Antraciclinas Antimetabólito Cáncer DNA topoisomerase (ATP-hydrolysing) Pirimidina derivado Enzima Fluor Compuesto orgánico Inhibidor topoisomerase II Inhibidor enzima Isomerases Glándula mamaria patología Seno patología Platino II Complejo Pirimidina nucleósido Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20283483
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjc.6604322 
https://dx.doi.org/10.1038/sj.bjc.6604322
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604322\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1327\";s:8:\"\u0000*\u0000epage\";s:4:\"1335\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"JULKA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"P. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"CHACKO, R. T\";i:1;s:10:\"DHINDSA, N\";i:2;s:12:\"MILLER, I. D\";i:3;s:5:\"MA, D\";i:4;s:6:\"LIN, B\";i:5;s:10:\"AWASTHY, B\";i:6;s:13:\"PEROUOU, C. M\";i:7;s:6:\"NAG, S\";i:8;s:10:\"PARSHAD, R\";i:9;s:7:\"NAIR, A\";i:10;s:8:\"OH, D. S\";i:11;s:5:\"HU, Z\";i:12;s:14:\"KOPPIKER, C. B\";i:13;s:7:\"NAIR, S\";i:14;s:8:\"DAWAR, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604322\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1327\";s:8:\"\u0000*\u0000epage\";s:4:\"1335\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"JULKA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"P. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"CHACKO, R. T\";i:1;s:10:\"DHINDSA, N\";i:2;s:12:\"MILLER, I. D\";i:3;s:5:\"MA, D\";i:4;s:6:\"LIN, B\";i:5;s:10:\"AWASTHY, B\";i:6;s:13:\"PEROUOU, C. M\";i:7;s:6:\"NAG, S\";i:8;s:10:\"PARSHAD, R\";i:9;s:7:\"NAIR, A\";i:10;s:8:\"OH, D. S\";i:11;s:5:\"HU, Z\";i:12;s:14:\"KOPPIKER, C. B\";i:13;s:7:\"NAIR, S\";i:14;s:8:\"DAWAR, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604322\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604322\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1327\";s:8:\"\u0000*\u0000epage\";s:4:\"1335\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"JULKA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"P. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"CHACKO, R. T\";i:1;s:10:\"DHINDSA, N\";i:2;s:12:\"MILLER, I. D\";i:3;s:5:\"MA, D\";i:4;s:6:\"LIN, B\";i:5;s:10:\"AWASTHY, B\";i:6;s:13:\"PEROUOU, C. M\";i:7;s:6:\"NAG, S\";i:8;s:10:\"PARSHAD, R\";i:9;s:7:\"NAIR, A\";i:10;s:8:\"OH, D. S\";i:11;s:5:\"HU, Z\";i:12;s:14:\"KOPPIKER, C. B\";i:13;s:7:\"NAIR, S\";i:14;s:8:\"DAWAR, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604322\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1327\";s:8:\"\u0000*\u0000epage\";s:4:\"1335\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"JULKA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"P. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"CHACKO, R. T\";i:1;s:10:\"DHINDSA, N\";i:2;s:12:\"MILLER, I. D\";i:3;s:5:\"MA, D\";i:4;s:6:\"LIN, B\";i:5;s:10:\"AWASTHY, B\";i:6;s:13:\"PEROUOU, C. M\";i:7;s:6:\"NAG, S\";i:8;s:10:\"PARSHAD, R\";i:9;s:7:\"NAIR, A\";i:10;s:8:\"OH, D. S\";i:11;s:5:\"HU, Z\";i:12;s:14:\"KOPPIKER, C. B\";i:13;s:7:\"NAIR, S\";i:14;s:8:\"DAWAR, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6604322\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"98\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1327\";s:8:\"\u0000*\u0000epage\";s:4:\"1335\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"JULKA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"P. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:12:\"CHACKO, R. T\";i:1;s:10:\"DHINDSA, N\";i:2;s:12:\"MILLER, I. D\";i:3;s:5:\"MA, D\";i:4;s:6:\"LIN, B\";i:5;s:10:\"AWASTHY, B\";i:6;s:13:\"PEROUOU, C. M\";i:7;s:6:\"NAG, S\";i:8;s:10:\"PARSHAD, R\";i:9;s:7:\"NAIR, A\";i:10;s:8:\"OH, D. S\";i:11;s:5:\"HU, Z\";i:12;s:14:\"KOPPIKER, C. B\";i:13;s:7:\"NAIR, S\";i:14;s:8:\"DAWAR, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:201:\"A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer : prediction of response using molecular profiling\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
